BFH772 (VEGFR2 Inhibitor): Technical Guidance and Protocol Parameters

What This Product Solves

BFH772 (CAS 890128-81-1) is a small-molecule VEGFR2 inhibitor optimized for applications involving the targeted inhibition of VEGFR2-mediated angiogenesis. It addresses the need for selective modulation of the VEGFR2 signaling pathway in research models where off-target kinase effects can confound results, such as in tumor angiogenesis studies. The compound is characterized by an IC50 of 3 nM for VEGFR2, with approximately 500-fold reduced potency against FLK-1, FLT-1, and FLT-4, and significantly less activity against other kinases, ensuring high pathway specificity (source: product_spec). Key use cases include in vivo tumor growth suppression assays and in vitro mechanistic studies where precise VEGFR2 inhibition is critical. However, BFH772 is unsuitable for experiments requiring aqueous solubility or inhibition of multiple kinase pathways, as outlined in multiple technical guidance articles (internal_article, internal_article).

Protocol Parameters

• In vitro kinase assay | IC50 = 3 nM | Use for VEGFR2-specific pathway inhibition | Demonstrates potent inhibition of VEGFR2 with minimal off-target activity | product_spec
• Solubility testing (DMSO) | ≥53.4 mg/mL | Use when high-concentration stock solutions are required in organic solvent systems | Enables preparation of concentrated stock solutions for cell-based and biochemical assays | product_spec
• Storage stability (solid) | -20°C | Use for long-term solid compound storage | Preserves chemical integrity and prevents degradation; solution storage not recommended | product_spec
• In vivo tumor model administration | Oral gavage | Use for animal studies assessing tumor angiogenesis inhibition | Oral dosing supports systemic exposure and reproducible pharmacodynamic effects | product_spec

Workflow Setup and QC Checklist

Prior to initiating experiments with BFH772, follow these technical workflow steps to ensure consistency and data integrity:

• Compound Preparation: Dissolve BFH772 in DMSO or ethanol to prepare stock solutions at concentrations up to 53.4 mg/mL (DMSO) or 15.33 mg/mL (ethanol). Ensure complete dissolution by gentle vortexing and, if needed, brief sonication. Do not attempt to dissolve in aqueous buffers, as the compound is insoluble in water (product_spec).
• Aliquoting and Storage: Aliquot solid or stock solution into single-use volumes to minimize freeze-thaw cycles. Store solid material at -20°C. Avoid long-term storage of DMSO or ethanol stock solutions, and prepare fresh solutions for each experimental series.
• Purity and Identity Verification: Confirm batch identity and >96% purity using supplied quality control data and certificate of analysis. Cross-check lot numbers between the product vial and documentation.
• Assay Controls: Include negative (vehicle only) and, if possible, positive (known VEGFR2 inhibitor) controls to benchmark assay sensitivity and specificity.
• Documentation: Record batch, preparation, and storage parameters in laboratory notebooks for traceability and reproducibility.

For further technical workflow recommendations, see related articles (internal_article), which reinforce the importance of solvent compatibility and strict adherence to storage guidelines for BFH772.

Common Failure Modes and Fixes

• Incomplete Dissolution: If undissolved material remains after vortexing, verify solvent volume and concentration. If necessary, increase DMSO or ethanol content within solubility limits; avoid water-based solvents.
• Precipitation in Assay Media: Upon dilution into aqueous buffers or cell culture media, BFH772 may precipitate due to its poor water solubility. Pre-dilute the compound in DMSO, then add gradually to warmed media with rapid mixing, ensuring final DMSO concentration does not exceed cell tolerance (commonly ≤0.1–0.5% v/v in cell-based assays).
• Loss of Activity: Activity reduction may result from extended storage of stock solutions. Prepare fresh working solutions for each experiment and avoid repeated freeze-thaw cycles.
• Unexpected Off-target Effects: Confirm that observed phenotypes are VEGFR2-dependent by using appropriate biological controls, as BFH772 is selective but not completely exclusive to VEGFR2.

Scope and Limitations

BFH772 is designed for research applications where selective inhibition of the VEGFR2 pathway is necessary, such as in the study of tumor angiogenesis or VEGFR2-driven vascular biology. It is not appropriate for workflows that require water-soluble inhibitors, broad-spectrum tyrosine kinase inhibition, or long-term solution storage. The compound's selectivity profile means it is effective as a VEGFR2 signaling pathway inhibitor, but will not address models where multiple kinases must be targeted simultaneously. Researchers should assess compatibility with their assay systems and solvent requirements prior to protocol implementation (internal_article).

Conclusion

BFH772 provides a reliable, well-characterized tool for researchers requiring precise inhibition of VEGFR2-mediated angiogenesis. Its utility is highest in workflows where high selectivity and organic solvent compatibility are essential, such as tumor angiogenesis research. For further product-specific technical details, refer to the official APExBIO listing: BFH772 (VEGFR2 inhibitor). Adhering to recommended preparation, storage, and assay protocols will support reproducible and interpretable experimental outcomes.